Century Therapeutics (Century Therapeutics) EPS (Basic) : $-2.21 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics EPS (Basic)?

Century Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $-0.45. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.21.

Century Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.45. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.21.

Century Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.45. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -1.89.

During the past 3 years, the average EPS without NRI Growth Rate was -18.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Century Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -18.50% per year. The lowest was -66.80% per year. And the median was -42.65% per year.

Century Therapeutics EPS (Basic) Historical Data

The historical data trend for Century Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics EPS (Basic) Chart

Century Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-5.88

-1.28

-2.96

-2.27

-2.30

Century Therapeutics Quarterly Data
	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial														-0.53	-0.56	-0.55	-0.65	-0.45

Century Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Century Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-136.673	-	0)	/	59.314
	=	-2.30

Century Therapeutics's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-28.062	-	0)	/	62.297
	=	-0.45

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.21

Century Therapeutics (NAS:IPSC) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Century Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Century Therapeutics (Century Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

3675 Market Street, Philadelphia, PA, USA, 19104

Website

https://www.centurytx.com

Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.

Executives

Luis Borges	officer: Chief Scientific Officer	TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Daphne Quimi	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez	director	ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta	director	3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva	director	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky	officer: President of R&D	C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Adrienne Farid	officer: Chief Operations Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Gregory Russotti	officer: Chief Technology Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Osvaldo Flores	officer: Chief Executive Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr	officer: VP of Finance and Operations	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104